Tomi Hendrayana
Tomi Hendrayana
School of Pharmacy - Institut Teknologi Bandung
Email yang diverifikasi di fa.itb.ac.id
JudulDikutip olehTahun
Anticancer dose adjustment for patients with renal and hepatic dysfunction: from scientific evidence to clinical application
T Hendrayana, A Wilmer, V Kurth, I Schmidt-Wolf, U Jaehde
Scientia pharmaceutica 85 (1), 8, 2017
52017
Variability in fluorouracil exposure during continuous intravenous infusion
T Hendrayana, V Kurth, L Krolop, P Kenny, R Axel Hilger, ...
International Journal of Clinical Pharmacologyand Therapeutics 50 (1), 82, 2012
42012
Provision of Patient Medication Counseling Service In A Tertiary-Care Eye Hospital In Bandung: A Gap Analysis of Patient’s Need, Standard and Service Provider Resources
T Hendrayana, Z Zazuli, G Fadhila, NS Cahyono
Indonesian Journal of Pharmacy 28 (4), 232, 2017
2017
ANALISIS KESESUAIAN DOSIS PADA PASIEN GANGGUAN FUNGSI GINJAL DI SUATU RUMAH SAKIT PENDIDIKAN DI KOTA BANDUNG
Z Zazuli, T Hendrayana, B Pratiwi, C Rahayu
Acta Pharmaceutica Indonesia 42 (1), 42-49, 2017
2017
Variability of systemic fluorouracil (5-FU) exposure during continuous infusion: there is a need for TDM
T Hendrayana, P Kenny, RA Hilger, I Schmidt-Wolf, YD Ko, U Jaehde
THERAPEUTIC DRUG MONITORING 33 (4), 548-548, 2011
2011
IV-31 Tomi Hendrayana Population pharmacokinetic (PK) model for fluorouracil (5-FU) accounting for irregularities in infusion rate
T Hendrayana, RA Hilger, U Fuhr, IGH Schmidt-Wolf, YD Ko, U Jaehde
Sistem tidak dapat melakukan operasi ini. Coba lagi nanti.
Artikel 1–6